collagen type I trimeric cross-linked peptide

Subscribe to Selected New Research on collagen type I trimeric cross-linked peptide

441 relevant articles (10 outcomes, 43 trials/studies) found for this Bio-Agent

Description: contains trifunctional cross-linking amino acid pyridinoline; marker for alveolar bone loss; amino acid sequence & structure in first source

Also Known As:

C-telopeptide; C-terminal type I collagen telopeptide; CTCLP; CTx telopeptide; N-telopeptide; N-terminal type I collagen telopeptide; NTx telopeptide; i-ICTP; pyridinoline cross-linked carboxy-terminal telopeptide, collagen type I; serum ICTP; serum carboxyterminal telopeptide type I collagen; trimeric cross-linked peptide collagen type I

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins

Proteins: 58433

Scleroproteins: 11

Extracellular Matrix Proteins: 904

Collagen: 22166

Fibrillar Collagens: 220

Collagen Type I: 3157

collagen type I trimeric cross-linked peptide: 441

Peptides: 16375

collagen type I trimeric cross-linked peptide: 441

Macromolecular Substances: 43

Polymers: 3257

Biopolymers: 137

Collagen: 22166

Fibrillar Collagens: 220

Collagen Type I: 3157

collagen type I trimeric cross-linked peptide: 441

Experts

1.	Vignon, E: 2 articles (12/2006 - 10/2003)
2.	Garnero, P: 2 articles (12/2006 - 10/2003)
3.	Conrozier, T: 2 articles (12/2006 - 10/2003)
4.	Karamanos, N K: 2 articles (06/2006 - 03/2004)
5.	Christgau, Stephan: 2 articles (06/2004 - 01/2002)
6.	Christgau, S: 2 articles (01/2004 - 10/2003)
7.	Nakada, Jojiro: 2 articles (06/2003 - 07/2002)
8.	Fukumitsu, Nobuyoshi: 2 articles (06/2003 - 07/2002)
9.	Uchiyama, Mayuki: 2 articles (06/2003 - 07/2002)
10.	Mori, Yutaka: 2 articles (06/2003 - 07/2002)

Related Diseases

1.	Bone Resorption 01/01/2003 - "Urinary excretion of the marker of bone resorption (cross-linked N-telopeptide) was lower with SR than with placebo in the STRATOS study. " 04/01/1999 - "Urinary N telopeptide, a measure of bone resorption, also increased during the studies. " 01/01/1999 - "Throughout the study the marker of bone resorption, serum ICTP, was above normal, with a peak (mean values 67-69% above baseline) at 1 week (p = 0.0002) to 1 month (p < 0.0001). " 04/24/2009 - "Consistent with an increase in bone resorption, the serum C-telopeptide level was 25% higher in transgenic mice than in wild-type littermates. " 10/14/2008 - "However, C-telopeptide levels (bone resorption marker) were not significantly different between the two groups. " Order ALL the reference details at left...
2.	Postmenopausal Osteoporosis 04/01/2000 - "These findings and the values of serum ICTP, PICP and BGP in pre- and postmenopausal women obtained in this study are expected to be very useful for treatment of postmenopausal osteoporosis." 01/01/1994 - "We conclude that serum ICTP does reflect bone metabolism in postmenopausal osteoporosis, but it is not a sensitive marker of the changes in bone resorption induced by hormone replacement therapy, and it does not correspond with other measures of bone resorption during anabolic steroid therapy." 12/01/2004 - "METHODS AND RESULTS: Using selected data from clinical studies involving 174 women with postmenopausal osteoporosis (PMO), a classical multicompartmental pharmacokinetic-pharmacodynamic (PK-PD) model was developed that accurately described the PK of i.v. ibandronate in plasma and urine and urinary excretion of the C-telopeptide of the alpha chain of type I collagen (uCTX), a sensitive biomarker of PD response to ibandronate. " 06/01/2000 - "Levels of C-telopeptide fragments of collagen type I enable the monitoring and early adjustment of clodronate therapy in patients with postmenopausal osteoporosis." 06/01/2000 - "We monitored the efficacy of therapy with clodronate, a bisphosphonate drug, in women with postmenopausal osteoporosis, using urinary immunoenzymatic assay of C-telopeptide of collagen type I, an eight amino acid fragment (collagen fragment) of the C-telopeptide of the alpha1-chain of collagen type I (EKAHDGGR). " Order ALL the reference details at left...
3.	Neoplasm Metastasis (Metastasis) 05/01/2003 - "Similarly the treatment of mice bearing bone metastasis with an MMP inhibitor led to a significant reduction of serum ICTP and CTX, and osteolytic lesions. " 01/01/2005 - "Serum ICTP level is more useful in staging metastasis. " 04/01/1999 - "Serum ICTP levels in patients with bone metastasis showed a significant downward trend in response to hormonal treatment. " 01/01/1999 - "CONCLUSIONS: Serum ICTP appears to be the leading marker of bone metastases from BC. " 08/01/1998 - "These results indicate that the measurement of serum ICTP concentration is useful for detecting and monitoring HCC patients with bone metastasis." Order ALL the reference details at left...
4.	Osteoporosis 06/01/2003 - "ELISA was developed for detection of urinary N-telopeptide (NTx) as an osteoporosis marker. " 08/01/1997 - "Thus, serum ICTP is better than other peripheral markers in monitoring LT4 suppressive therapy in patients at increased risk for osteoporosis such as perimenopausal women." 06/11/2004 - "Serum levels of c-telopeptide, a marker of bone resorption, are increased in MCHR1(-/-) mice, indicating that the MCHR1(-/-) mice have a high bone turnover osteoporosis. " 06/01/2002 - "CONCLUSION: Our data suggest that N-telopeptide levels could be used as a tool for the screening of osteoporosis and for selecting those inflammatory bowel disease patients where bone mineral density measurement is indicated." 06/01/2002 - "Using receiver operator characteristic curves N-telopeptide concentrations of > 40 (30) nmol N-telopeptides/mmol creatinine were chosen as best cut-off values to exclude osteoporosis at the lumbar spine (femoral neck). " Order ALL the reference details at left...
5.	Bone Diseases (Bone Disease) 11/01/1998 - "Our data indicate that serum ICTP levels predict significantly the response to bisphosphonate therapy in patients with advanced malignant osteolytic bone disease. " 12/01/2003 - "Relationships between the rate of bone resorption (measured by urinary N-telopeptide (Ntx) excretion) and a range of skeletal complications have been evaluated in patients with metastatic bone disease. " 09/01/1997 - "In this study, we investigated whether the degree of beta-isomerization within C-telopeptide of alpha 1 chain of type I collagen was altered in Paget's disease compared with other bone diseases with no alteration of bone structure. " 11/01/1998 - "Significant predictors of non-progressive bone disease were urinary pyridinoline and serum ICTP levels; significant predictors of reduction in pain intensity were urinary free deoxypyridinoline and serum ICTP levels. " 06/15/2000 - "Recent developments suggest that biochemical markers of bone remodeling, such as the bone collagen breakdown product N-telopeptide and the bone formation marker known as bone specific alkaline phosphatase, hold great promise as clinical tools for the management of patients with metastatic bone disease. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	collagen type I trimeric cross-linked peptide
2.	Collagen
3.	Collagen Type I (Type I Collagen)
4.	Osteocalcin
5.	Alkaline Phosphatase
6.	Clodronic Acid (Clodronate)
7.	deoxypyridinoline
8.	Biological Markers (Surrogate Marker)
9.	Alendronate (Alendronate Sodium)
10.	Calcium

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Aftercare (After-Treatment)
3.	Ovariectomy (Oophorectomy)
4.	Bed Rest (Bedrest)
5.	Neoadjuvant Therapy

Best Treatments:
Research Summary Report
on Bone Resorption

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 292 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>